KYN-001

KYN‑001 is Kynova Therapeutics’ first development program: an injectable, rationally engineered peptide therapeutic candidate designed for atopic dermatitis. It was conceived to intervene where chronic disease in atopic skin is sustained – at the intersection of dysregulated inflammation, impaired barrier function, and a disrupted local tissue environment.

Rather than targeting a single pathway in isolation, KYN‑001 is built as a multi‑mechanism construct that integrates complementary biological motifs into one formulation. The goal is to achieve a more complete, durable resolution of disease activity while maintaining a practical route of administration for real patients in dermatology settings.

  • KYN‑001 is formulated as an injectable construct to balance several priorities:

    • Achieving sufficient exposure at relevant skin and immune compartments.

    • Maintaining stability and manufacturability at a preclinical and eventual clinical scale.

    • Allowing for dosing paradigms that fit chronic dermatology practice and patient lifestyles.

  • Integrity, creativity, and empathy shape the way we work. These aren't just words—they’re the foundation of everything we build.

  • What began as a passion project has evolved into something more. We’re proud of where we’ve been and even more excited for what’s ahead. What sets us apart isn’t just our process—it’s the intention behind it. We take time to understand, explore, and create with purpose at every turn.